BG Medicine is a diagnostics company focused on the development and commercialization of novel cardiovascular tests. The company has two products: the Galectin-3 test for use in patients with chronic heart failure and the CardioSCORE test for the risk prediction of major cardiovascular events.
The company announced today that it has appointed Paul Sohmer, M.D., as its president and chief executive officer and a member of its Board of Directors. He replaces Eric Bouvier as CEO. Dr. Sohmer brings more than 25 years of experience leading the growth of commercial-stage companies focused on diagnostics, laboratory services, and medical devices.
Dr. Sohmer most recently served as president and CEO of Viracor-IBT Laboratories, a diagnostic and research laboratory specializing in allergy, immunology, and infectious disease testing. Prior to that, he was CEO of Orthocon, a developer, manufacturer, and marketer of implantable medical products. Sohmer also has served as interim CEO of Cylex and CEO of Pathway Diagnostics.
In addition, Dr. Sohmer was president and CEO of Neuromedical Systems before its acquisition by TriPath Imaging. He then became TriPath's chairman, president, and CEO before it was acquired by the giant medical technology company Becton, Dickinson. Earlier in his career, Sohmer served as president and CEO of Genetrix, a genetic testing lab that was acquired by Genzyme.
Dr. Sohmer said, "Our challenge now is to unlock the clinical and commercial potential of the company's innovative diagnostic tests. Going forward we will work to enhance and leverage our assets to create a commercial engine that will allow us to grow and drive our margin."
For additional information about BG Medicine and its two innovative diagnostic tests, please visit www.bg-medicine.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html